Novast, a pharmaceutical company that develops and commercializes generic drugs, raised c. $141m in a Legend Capital-led funding round. Shiyu Capital, Xiamen C&D, the Ministry of Commerce, China Merchants Group, Highlight Capital and Highsino Group also participated in the round. "The first goal of Novast is to achieve a breakthrough in the internationalization of high-end oral solid preparations made in China and to provide high-quality and inexpensive drugs for the US prescription drug market. The company's second goal is to bring high-end pharmaceutical products into the domestic market and into other counties for the benefit of mankind," Zhang Guohua, Novast Founder and President.